The estimated Net Worth of Vii L P Canaan Partners Vii... is at least $27.8 Milión dollars as of 25 October 2018. Vii Vii owns over 72,980 units of Marinus Pharmaceuticals Inc stock worth over $7,299,397 and over the last 11 years Vii sold MRNS stock worth over $20,513,931.
Vii has made over 32 trades of the Marinus Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Vii sold 72,980 units of MRNS stock worth $197,776 on 25 October 2018.
The largest trade Vii's ever made was selling 674,771 units of Marinus Pharmaceuticals Inc stock on 23 October 2013 worth over $10,465,698. On average, Vii trades about 124,420 units every 49 days since 2013. As of 25 October 2018 Vii still owns at least 5,251,365 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Vii Vii stock trades at the bottom of the page.
Vii's mailing address filed with the SEC is 285 RIVERSIDE AVENUE285 RIVERSIDE AVENUE, SUITE 250SUITE 250, WESTPORTWESTPORT, CTCT, 0688006880.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... a Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: